Litigation Details for Wright v. Boehringer Ingelheim Pharmaceuticals, Inc. (N.D. Ohio 2020)
✉ Email this page to a colleague
Wright v. Boehringer Ingelheim Pharmaceuticals, Inc. (N.D. Ohio 2020)
Docket | ⤷ Try a Trial | Date Filed | 2020-01-29 |
Court | District Court, N.D. Ohio | Date Terminated | |
Cause | 28:1332 Diversity-Product Liability | Assigned To | Donald C. Nugent |
Jury Demand | Plaintiff | Referred To | |
Patents | 9,000,002 | ||
Link to Docket | External link to docket |
Biologic Drugs cited in Wright v. Boehringer Ingelheim Pharmaceuticals, Inc.
Details for Wright v. Boehringer Ingelheim Pharmaceuticals, Inc. (N.D. Ohio 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2020-01-29 | 1 | Complaint | B) Predicted Affinity (kcal/mol) ADMA|-5.9+0.2 Ranitidine|__-6.1+0.1 69. …amp; Hanburys Ltd. was awarded Patent No. 4,128,658 by the U.S. Patent and Trademark Office in December…successor-in-interest to the companies that initially developed, patented, and commercialized the molecule known as ranitidine | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |